We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVMI:NASDAQNova Ltd. Analysis

Data as of 2026-06-21 - not real-time

$575.31

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Nova Ltd. (NVMI) is trading at $575.31, comfortably above its 20‑day ($526.92) and 50‑day ($517.86) SMAs and the 200‑day SMA ($407.22), confirming a strong bullish bias. The MACD histogram is positive (+5.92) and the MACD line sits well above its signal line, while the RSI at 58 indicates momentum is still intact without being overbought. Volume is increasing and the price is holding well above the identified support at $474.35, with the next resistance near $616, suggesting room for short‑term upside.
Fundamentally, the company posted 10.3% YoY revenue growth to $235.3 M and beat consensus earnings, raising Q2 guidance 3.8% above expectations. However, the current PE of 71.9× versus an industry average of 38.1× and a DCF fair value of $87.61 imply the stock is heavily overvalued, with an upside/downside projection of only ~3.9%. The balance sheet shows ample cash ($1.10 B) but a high debt‑to‑equity of 57.7% and a beta of ~2.7, indicating elevated volatility and market risk. The consensus recommendation is a "strong buy" amid extreme greed sentiment, but the valuation gap and geopolitical exposure temper enthusiasm for longer horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical setup with price above key SMAs
  • Earnings beat and raised guidance
  • Increasing volume supporting momentum

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth and high operating margins
  • Persistently high valuation multiples relative to peers
  • Exposure to semiconductor cycle and geopolitical tensions

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • DCF fair value far below current price
  • High beta and volatility indicating market sensitivity
  • Potential headwinds from regulatory/export controls

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin29.21%
P/E Ratio71.9
ROE22.25%
ROA8.40%
Debt/Equity57.67
P/B Ratio13.9
Op. Cash Flow$217.1M
Free Cash Flow$122.4M
Industry P/E38.1

Technical Analysis

TrendBullish
RSI58.3
Support$474.35
Resistance$615.99
MA 20$526.92
MA 50$517.86
MA 200$407.22
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Fair Value$87.61
Target Price$597.63
Upside/Downside3.88%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.69
Volatility82.98%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.